

+

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Completion if Known	
		Application Number	
		Filing Date	
		First Named Inventor	Dean, Herbert et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	

918 U.S. PTO
09/717746

0918 W.S. PTO
09/717746
11/21/00

#2
AKO
3-1-01

[illegible][illegible]

Examiner Signature		Date Considered	1/27/02
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Complete if Known

Application Number

Filing Date

First Named Inventor

D an, H rb rt et al.

Group Art Unit

Examiner Name

Attorney Docket Number

Sheet

2

of

2

(use as many sheets as necessary)

09/17746
JCS18 U.S. PRO
11/21/00

Examiner Signature		Date Considered	1/22/2
--------------------	---	-----------------	--------

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Sheet	1	of	4
		Application Number	09/717,746
		Filing Date	11/21/2000
		First Named Inventor	Dean, Herbert M. et al.
		Group Art Unit	1614
		Examiner Name	
		Attorney Docket Number	

[illegible][illegible]

Examiner Signature		Date Considered	1/27/12
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

APR 16 2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	09/717,746
Filing Date	11/21/2000
First Named Inventor	Dean, Herbert M. et al.
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	

TECH CENTER 1600/2600

APR 19 2001

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
AG	AA	JONES, PETER H. et al., Prevention of coronary heart disease in 1994: evidence for intervention, Heart Disease and Stroke 1994;3:290-296.
	AB	Acc/AHA Guidelines for the management of patients with acute myocardial infarction. The American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC 1996;28:1328-1400.
	AC	MCCORMICK, DANNY et al., Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction. Missed opportunities for prevention?, Archives of Internal Medicine 1999; 159:561-567.
	AD	ANTMAN, ELLIOTT M. et al., A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction, JAMA 1992;268:240-248.
	AE	YUSUF, SALIM et al., Overview of results of randomized clinical trials in heart disease, Part 1, JAMA 1988; 268:2088-2093.
	AF	STAMPFER, MEIR J. et al., Vitamin E consumption and the risk of coronary heart disease in women, New England Journal of Medicine 1993;328:1444-1449.
	AG	RIMM, ERIC B. et al., Vitamin E consumption and the risk of coronary heart disease in men, New England Journal of Medicine 1993;328:1450-1456.
	AH	WELCH, GEORGE N. et al., Homocysteine and atherothrombosis, New England Journal of Medicine 1998;339:1042-1050.
	AI	Final report on the aspirin component of the ongoing physicians' health study, Steering Committee of the Physicians' Health Study Group, New England Journal of Medicine 1989;321:129-135.
	AJ	PETO, R. et al., Randomised trial of prophylactic daily aspirin in British male doctors. Peto R, Gray R, Collins R, Wheatley K, et al. British Medical Journal 1988;297:313-316.
AG	AK	HENNEKENS, C. H. et al., An overview of the British and American aspirin studies. Hennekens CH, Peto R, Hutchison GB, Doll R. New England Journal of Medicine 1988;318:923-924.

Examiner Signature

Date Considered

1/27/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		APR 16 2001		Compl te if Kn wn	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/717,746
				Filing Date	11/21/2000
				First Named Inventor	D an, Herbert M. t al.
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
LD	AL	MANSON, JOANN E. et al., Aspirin in the primary prevention of angina pectoris in a randomized trial of United States Physicians, The American Journal of Medicine. 1990;89:772-776.
	AM	Collaborative overview of randomised trials of antiplatelet therapy- 1: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, Antiplatelet Trialists' Collaboration, British Medical Journal 1994;308:81-106.
	AN	KRUMHOLZ, HARLAN M. et al., Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes, Annals of Internal Medicine 1996;124:292-298.
	AO	RIDKER, PAUL M. et al., Clinical characteristics of nonfatal myocardial infarction among individuals on prophylactic low-dose aspirin therapy, Circulation 1991;84:708-711.
	AP	Coronary artery disease, Caremark's Clinical Update, August 2000.
	AG	Randomised trial of cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian simvastatin survival study, The Scandinavian Simvastatin Survival Study Group, Lancet 1994;334:1383-1389.
	AR	GOLDMAN, LEE et al., Cost-effectiveness of HMB-CoA reductase inhibition for primary and secondary prevention of coronary heart disease, JAMA. 1991;265:1145-1151.
	AS	LAW, M. R. et al., By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? British Medical Journal 1993;308:167-372.
	AT	Guidelines for using serum cholesterol, high density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults, Clinical Guideline, Part 1, American College of Physicians, Annals of Internal Medicine 1996;124:515-157.
	AV	DOWNS, JOHN R. et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA 1998;279:1615-1622.
	AV	SHEPHERD, JAMES et al., Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia, New England Journal of Medicine 1995;333:1301-1307.

Examiner Signature		Date Considered	1/27/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

● 止


Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

APR 16 2001
DISCLOSURE
PATENT & TRADEMARK

RECEIVED
APR 19 2001
TECH CENTER 1600/2900



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.